Business · 03/10/2017

FDA Releases Draft Guidance for Industry on Refuse-to-Receive Standards for Abbreviated New Drug Applications

The US Food and Drug Administration (FDA) has published a draft guidance to help pharmaceutical companies prepare for submitting abbreviated new drug applications (ANDAs) and prior approval supplements, addressing common questions and issues related to the review process.